AVITA Medical, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $RCEL in the last 30 days.
See all $RCEL insider activity →CareDx (CDNA), AVITA Medical (RCEL), Azenta (AZTA), and Hinge Health (HNGE) reached 52-week highs on October 2, 2026. CDNA reported $132M Q2 revenue, up 52% YoY. RCEL saw 18% Q2 revenue growth. AZTA reported 12% Q3 revenue growth. HNGE saw 53% Q2 revenue growth and acquired Cylinder Health for $105M.
Modular Medical (MODD) received FDA clearance for software enhancements to its Pivot insulin pump, planning a commercial launch in October 2026. Galmed (GLMD) shareholders approved all proposals, including a name change. Pro-Dex (PDEX) reported strong Q4 results with 17% sales growth. eHealth (EHTH) saw after-hours gains despite a Q2 net loss. Connect Biopharma (CNTB) will present at a conference and report Phase 2 trial results. AVITA Medical (RCEL) expects full-year revenue of $86M-$89M.
TD Cowen raised its price target on Avita Medical (RCEL) to $14.00 from $12.00, citing confidence in PermeaDerm's commercial potential. The stock is up 185% YTD. Avita reported Q2 revenue of $21.7M, beating estimates, and BTIG upgraded its rating to Buy with a $11.00 target. PermeaDerm trial data showed economic benefits over allograft.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning RCEL (AVITA Medical, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent RCEL coverage spans earnings, financial news and market movers.
Guidance lift and revenue growth suggest continued buying interest.
Conference exposure may attract investors; revenue growth supports outlook.
Positive trial data and analyst upgrades suggest near-term upside for RCEL.
Cost and workflow advantages versus allograft, alongside comparable clinical outcomes, can improve adoption odds and valuation expectations.
Management is signaling a specific breakeven timeline and cost discipline, with reimbursement normalization and underpenetration as key growth levers.
AlphAI scores every news story that mentions RCEL with an AI model for sentiment and relevance, and aggregates insider trades from AVITA Medical, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
CareDx (CDNA), AVITA Medical (RCEL), Azenta (AZTA), and Hinge Health (HNGE) reached 52-week highs on October 2, 2026. CDNA reported $132M Q2 revenue, up 52% YoY. RCEL saw 18% Q2 revenue growth. AZTA reported 12% Q3 revenue growth. HNGE saw 53% Q2 revenue growth and acquired Cylinder Health for $105M.
2 min readModular Medical (MODD) received FDA clearance for software enhancements to its Pivot insulin pump, planning a commercial launch in October 2026. Galmed (GLMD) shareholders approved all proposals, including a name change. Pro-Dex (PDEX) reported strong Q4 results with 17% sales growth. eHealth (EHTH) saw after-hours gains despite a Q2 net loss. Connect Biopharma (CNTB) will present at a conference and report Phase 2 trial results. AVITA Medical (RCEL) expects full-year revenue of $86M-$89M.
3 min readTD Cowen raised its price target on Avita Medical (RCEL) to $14.00 from $12.00, citing confidence in PermeaDerm's commercial potential. The stock is up 185% YTD. Avita reported Q2 revenue of $21.7M, beating estimates, and BTIG upgraded its rating to Buy with a $11.00 target. PermeaDerm trial data showed economic benefits over allograft.
2 min readAmylyx Pharmaceuticals (AMLX) rose 55.71% after positive Phase 3 LUCIDITY trial results for Avexitide. AVITA Medical (RCEL) gained 21.90% on cost-effective PermeaDerm-I study data. CNS Pharmaceuticals (CNSP) increased 12.04% following a strategic financing and pipeline pivot. Orchestra BioMed (OBIO) advanced 15.04% with strategic capital and hypertension program progress. NeOnc Technologies (NTHI) climbed 13.80% on encouraging Phase 2a NEO100 data.
4 min readAvita Medical (NASDAQ:RCEL) said it targets cash-flow breakeven in Q4 2025 as revenue grows. CEO Vance said the company can expand without adding sales reps for at least 18 months and cited data for RECELL, including a 36% shorter length of stay vs split-thickness grafting. Reimbursement issues are easing, with a simplified Medicare code planned for Jan. 1, 2027.
4 min readAvita Medical (NASDAQ:RCEL) reported Q2 net loss of $7.7M, nearly $3M better than Q1, with cash use down to $3.2M and cash of $11.1M at quarter end. The company raised its 2026 revenue outlook and said it is within Perceptive Advisors debt revenue covenants, including a $73M 2026 target. Q2 sales rose 18%.
7 min readAVITA Medical (RCEL) reported Q2 2026 revenue of $21.7M, up 18% year over year and 13% sequentially. RECELL revenue was $18.5M, Cohealyx $1.7M, and PermeaDerm $0.6M. Gross margin was 81.9%. Net loss was $7.7M ($0.25/share). Full-year 2026 guidance is $86M to $89M; cash flow breakeven targeted for Q4 2026.
7 min readAVITA Medical, Inc. (RCEL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 5, 2026, the Company and Stedical Scientific, Inc. (“Stedical”) entered into a Global Amendment of their existing distribution agreement and manufacturing agreement (the “Global Amendment”). Under the terms of the Gl
6 min readAvita Medical (RCEL) shares rose about 22% pre-open after the company reported Q2 revenue of $21.7M, up 18% YoY and about 8% above consensus, with adjusted loss per share of $0.25 vs $0.30 expected. The firm raised 2026 revenue guidance to $86M-$89M and reiterated cash-flow breakeven in Q4 2026. BTIG upgraded RCEL to Buy and set a $7 target.
4 min readAVITA Medical, Inc. (RCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven VALENCIA, Calif., August 6, 2026 (GLOBE NEWSWIRE) — AVITA Medical ® , Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care comp
6 min read
